共查询到19条相似文献,搜索用时 15 毫秒
1.
Priscilla Velentgas Anthony A. Amato Rhonda L. Bohn K. Arnold Chan Thomas Cochrane Donnie P. Funch Inna Dashevsky April L. Duddy Patricia Gladowski Steven A. Greenberg Judith M. Kramer Cheryl McMahill‐Walraven Cynthia Nakasato Claire M. Spettell Beth L. Syat Peter M. Wahl Alexander M. Walker Fang Zhang Jeffrey S. Brown Richard Platt 《Pharmacoepidemiology and drug safety》2012,21(12):1350-1358
2.
Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013–2014 and 2014–2015 seasons 下载免费PDF全文
Rongxia Li Brock Stewart Michael M. McNeil Jonathan Duffy Jennifer Nelson Alison Tse Kawai Roger Baxter Edward A. Belongia Eric Weintraub 《Pharmacoepidemiology and drug safety》2016,25(8):928-934
3.
4.
Pedro L. Moro Rongxia Li Penina Haber Eric Weintraub Maria Cano 《Expert opinion on drug safety》2013,12(9):1175-1183
ABSTRACTIntroduction: Annual influenza vaccine safety monitoring is an important component of the influenza vaccination program in the United States to ensure that vaccines are safe, which is important for maintaining public trust in the national vaccination program. This is specially the case for influenza vaccines since the antigen composition of the viruses of which the vaccine is made often changes from one season to the next, based on the circulating strain of influenza virus.Areas covered: This review describes the two surveillance systems used by the Centers for Disease Control and Prevention (CDC) to monitor the safety of influenza vaccines: 1) the Vaccine Adverse Event Reporting System (VAERS); and 2) the Vaccine Safety datalink (VSD).Expert opinion: VAERS and VSD are used routinely to monitor the safety of influenza vaccines in the United States, and over the years they have demonstrated their value in monitoring vaccine safety since their implementation in 1990. Both systems, although different, complemented each other well to study febrile seizures in young children following influenza vaccination during the 2010–2011 influenza season. Other examples of potential safety concerns after influenza vaccines are also presented and discussed. 相似文献
5.
6.
7.
The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study 下载免费PDF全文
Matthew F. Daley Christina L. Clarke Jason M. Glanz Stanley Xu Simon J. Hambidge James G. Donahue James D. Nordin Nicola P. Klein Steven J. Jacobsen Allison L. Naleway Michael L. Jackson Grace Lee Jonathan Duffy Eric Weintraub 《Pharmacoepidemiology and drug safety》2018,27(1):59-68
Purpose
To evaluate the safety of live attenuated influenza vaccine (LAIV) in children 2 through 17 years of age.Methods
The study was conducted in 6 large integrated health care organizations participating in the Vaccine Safety Datalink (VSD). Trivalent LAIV safety was assessed in children who received LAIV between September 1, 2003 and March 31, 2013. Eighteen pre‐specified adverse event groups were studied, including allergic, autoimmune, neurologic, respiratory, and infectious conditions. Incident rate ratios (IRRs) were calculated for each adverse event, using self‐controlled case series analyses. For adverse events with a statistically significant increase in risk, or an IRR > 2.0 regardless of statistical significance, manual medical record review was performed to confirm case status.Results
During the study period, 396 173 children received 590 018 doses of LAIV. For 13 adverse event groups, there was no significant increased risk of adverse events following LAIV. Five adverse event groups (anaphylaxis, syncope, Stevens‐Johnson syndrome, adverse effect of drug, and respiratory failure) met criteria for manual medical record review. After review to confirm cases, 2 adverse event groups remained significantly associated with LAIV: anaphylaxis and syncope. One confirmed case of anaphylaxis was observed following LAIV, a rate of 1.7 per million LAIV doses. Five confirmed cases of syncope were observed, a rate of 8.5 per million doses.Conclusions
In a study of trivalent LAIV safety in a large cohort of children, few serious adverse events were detected. Anaphylaxis and syncope occurred following LAIV, although rarely. These data provide reassurance regarding continued LAIV use. 相似文献8.
9.
Six‐year multi‐centre,observational, post‐marketing surveillance of the safety of the HPV‐16/18 AS04‐adjuvanted vaccine in women aged 10–25 years in Korea 下载免费PDF全文
Chul‐Jung Kim Rok Song Jing Chen Fernanda Tavares Da Silva Kusuma B. Gopala Joon Hyung Kim Dan Bi Jong Sup Park 《Pharmacoepidemiology and drug safety》2017,26(7):837-842
10.
11.
12.
13.
14.
PROTECTED‐UK – Clinical pharmacist interventions in the UK critical care unit: exploration of relationship between intervention,service characteristics and experience level 下载免费PDF全文
Nicola Rudall Catherine McKenzie June Landa Richard S. Bourne Ian Bates Rob Shulman 《The International journal of pharmacy practice》2017,25(4):311-319
15.
Brian Tiplady 《Human psychopharmacology》1992,7(2):139-141
This commentary argues that the conventional assessment of the reliability of psychological tests may be inappropriate in psychopharmacology. The conventional approach depends upon the assessment of differences between individuals rather than changes within individuals. It thus favours measures of trait, while those required for investigating drug-induced changes are measures of state. The sensitivity of a measure to change is a more useful criterion for inclusion in a test battery for the investigation of the effects of drugs. 相似文献
16.
Azadeh Sabetghadam Visweswaran Navaratnam Sharif Mahsufi Mansor 《Drug development research》2013,74(1):23-30
Preclinical Research |
17.
The burden and management of cytochrome P450 2D6 (CYP2D6)‐mediated drug–drug interaction (DDI): co‐medication of metoprolol and paroxetine or fluoxetine in the elderly 下载免费PDF全文
Muh. Akbar Bahar Eelko Hak Jens H.J. Bos Sander D. Borgsteede Bob Wilffert 《Pharmacoepidemiology and drug safety》2017,26(7):752-765
18.
Incidence,causative factors and mortality rates of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry 下载免费PDF全文
Janouk Diphoorn Simone Cazzaniga Chiara Gamba Jan Schroeder Antonella Citterio Alma Lisa Rivolta Giuseppe Danilo Vighi Luigi Naldi The REACT‐Lombardia study group 《Pharmacoepidemiology and drug safety》2016,25(2):196-203